Clinical trials: Central Line Associated Blood Stream Infections (CLABSI)
- Condition Central Line Associated Blood Stream Infections (CLABSI)
- Funder type Industry (pharma, biotech, devices)
Central Line Associated Blood Stream Infections (CLABSI)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN)…
- Trial name
- NCT06822426
- Testing
- (taurolidine and heparin) catheter lock solution, Heparin
- Where
- 24 sites in United States, Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- CorMedix Therapeutics
Infection, Hospital
Passive Disinfection Cap Compliance Study
Insertion and maintenance of central venous catheter (CVC) lines are common hospital procedures in patients, including those being treated for cancer.
- Trial name
- NCT03391960
- Testing
- Passive disinfection device
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Solventum US LLC
Surgery, Central Line Associated Blood Stream Infections (CLABSI)
BIP CVC Clinical Safety and Performance Study
The primary objective of this trial was to determine Bactiguard coated BIP CVC's safety and performance and compare it to corresponding standard uncoated CVC.
- Trial name
- NCT02811380
- Testing
- BIP CVC, Uncoated Standard CVC
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Bactiguard AB